Accelerate Drug Development with Praedicare's SYSTEM OF SYSTEMS (SOS) APPROACH
Revolutionizing Drug Development
Praedicare's SoS for Drug Development Approach has Transformed the Path to FDA/EMA Approval
Praedicare's revolutionary SoS approach accelerates drug development. With first-of-its kind integrated multiple wet lab systems, system of mathematical models, suite of AI tools, and clinical trial databases to give outcomes that are emergent properties that reduce timelines 2-3 times, >90% of costs, and maximize phase-by-phase success rates from preclinical phases to NDA/BLA.
Reduce Drug Development costs by up to up to 90%
Accelerate drug development cycle from bench to clinic by 2-3x
De-risk patient's lives by reducing death and adverse events by 50%
WHY CHOOSE US
Praedicare Reduces Costs, Accelerates Development, and Enhances Patient Safety
We are dedicated to transforming healthcare through our innovative solutions. By reducing drug development costs by up to 20x, accelerating the development cycle by 2-3x, and significantly improving patient safety, Praedicare is revolutionizing the healthcare landscape. Explore our cutting-edge technologies and discover how we are reshaping the future of healthcare, one advancement at a time.
Quantify. Predict. Cure.
Integrating laboratory experiments, mathematical models, morphism mapping, and machine-learning/A.I. to predict:
Rates of Response in Patients
How Many Patients Will Respond
Optimal Duration of Therapy
Doses to Minimize Failure & Resistance
Personalized Therapy
Preclinical Lab & Math
Modeling Solutions
Will drug be efficacious in humans? If so, at what dose? -Are there potential toxicity risks that can be identified early? If so, at what dose?
Are there potential opportunities to improve efficacy through drug combinations? If so, what drug(s) and doses?
How best to align our regulatory strategy, pre- clinical and clinical plans to mitigate risk?
Demonstration of commercial viability of drug to investors & partners
Helping Clients
Our predictions have been highly accurate through Phase III studies and beyond.
Accurately predict efficacy and toxicity signals during preclinical phase
Optimal drug doses for combinations using factorial design
Reduce drug development timelines using our quantitative forecasting
Data and models that we have generated has been used by clients throughout the regulatory process by international regulatory bodies
We can help clients identify potential collaborators and investors
Quantify. Predict. Cure.
Integrating laboratory experiments, mathematical models, morphism mapping, and machine-learning/A.I. to predict:
Rates of Response in Patients
How Many Patients Will Respond
Optimal Duration of Therapy
Doses to Minimize Failure & Resistance
Personalized Therapy
Preclinical Lab & Math
Modeling Solutions
Will drug be efficacious in humans? If so, at what dose? -Are there potential toxicity risks that can be identified early? If so, at what dose?
Are there potential opportunities to improve efficacy through drug combinations? If so, what drug(s) and doses?
How best to align our regulatory strategy, pre- clinical and clinical plans to mitigate risk?
Demonstration of commercial viability of drug to investors & partners
Helping Clients
Our predictions have been highly accurate through Phase III studies and beyond.
Accurately predict efficacy and toxicity signals during preclinical phase
Optimal drug doses for combinations using factorial design
Reduce drug development timelines using our quantitative forecasting
Data and models that we have generated has been used by clients throughout the regulatory process by international regulatory bodies
We can help clients identify potential collaborators and investors
Wet Lab Systems
Hollow-fiber models for infectious disease, oncology, immune system, and safety with 3D human organotype
models.
Math Modeling & AI Systems
Mathematical models to
predict performance in
clinical trials for clinical trial design and adaptive clinical trial design.
In Silico & Real Clinical Trial Design
Perform clinical trials and
research in North America and 28 African countries. Modeling to support clinical trials and dose selections.
Preclinical
Services
Hollow-fiber models for infectious disease, oncology, immune system, and safety with 3D human organotype
models.
Quantitative
Clinical Forecasting
Mathematical models to
predict performance in
clinical trials for clinical trial design and adaptive clinical trial design.
Clinical Trials &
Research
Perform clinical trials and
research in North America and 28 African countries. Modeling to support clinical trials and dose selections.
The Solution
The Problem
- Praedicare customizes preclinical wet lab models mapped to patients for quantitative prediction of clinical trial outcomes, significantly reducing risk, time and costs of developing safe and effective new drugs.
- Current new drug development efforts are unsustainable. 1 in 10 drugs that enter clinical trials never get approved. The cost, including failures, is greater than $1 billion over 12 to 15 years driving up the price of drugs for patients.
First-of-its-kind Systems of Systems based Drug
Development
Customized preclinical model technologies mathematically mapped to patients for quantitative prediction of patient responses, response rates, and optimal doses and toxicology with >90% accuracy.
Model Uses Include:
Optimized clinical trial design, including sample size and adaptive designs
Identify and develop biomarkers to optimize clinical trial design and provide biology-driven clinical trial therapeutic endpoints
Custom-made hollow fiber technology and 3D human organoids combined with advanced ‘omics, bulk and single cell sequencing for drug discovery, biomarkers, IP strengthening/submission, safety, and IND submissions.
Unique Biotech CRO for Drug Discovery, Development
& Clinical Trials
Customized preclinical model technologies mathematically mapped to patients for quantitative prediction of patient responses, response rates, and optimal doses and toxicology with >90% accuracy.
Model Uses Include:
Optimized clinical trial design, including sample size and adaptive designs
Identify and develop biomarkers to optimize clinical trial design and provide biology-driven clinical trial therapeutic endpoints
Custom-made hollow fiber technology and 3D human organoids combined with advanced ‘omics, bulk and single cell sequencing for drug discovery, biomarkers, IP strengthening/submission, safety, and IND submissions.
INTERESTED IN LEARNING MORE?
Contact Us Today
21
56
Number of Biopharma
Companies Worked With
Number of Projects
Worked On
INTERESTED IN LEARNING MORE?
Contact Us Today
49
Number of Biopharma
Companies Worked With
19
Number of Projects
Worked On